CRMD - CorMedix, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.6400
+0.0200 (+1.23%)
As of 1:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.6200
Open1.6500
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range1.5200 - 1.6900
52 Week Range0.1700 - 2.4000
Volume1,952,257
Avg. Volume3,924,217
Market Cap164.93M
Beta (3Y Monthly)3.96
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • ACCESSWIRE12 days ago

    Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix

    CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.

  • GlobeNewswire12 days ago

    Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE13 days ago

    CBD and Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / November 27, 2018 / CBD and biotech companies are on our radar this week. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Auris Medical Holding AG (EARS), CorMedix, ...

  • Associated Press25 days ago

    CorMedix: 3Q Earnings Snapshot

    On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 11 cents. The pharmaceutical and medical device company posted revenue of $372,500 in the period. Its adjusted ...

  • ACCESSWIRE26 days ago

    CorMedix Inc. Reports Third Quarter Financial Results and Provides Business Update

    Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 14, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing ...

  • ACCESSWIRElast month

    CorMedix Inc. to Report Third Quarter 2018 Financial Results on Wednesday, November 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 6, 2018 / CorMedix Inc. (NYSE: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...

  • ACCESSWIRElast month

    3 Healthcare Stocks Using Technology To Boost Growth

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Health technology is defined by the World Health Organization as the "application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives." Healthcare companies are taking a new and novel approach the health tech in the form of new innovation that takes the guesswork out of tracking health & reporting results. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Market activity in the United States appears to have picked up after the company's most recent announcement.

  • Investopedialast month

    Penny Stocks to Buy Using Technical Analysis for November 2018

    Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Lantheus, Editas Medicine, CorMedix, DXP Enterprises, Peabody Energy, and CommScope Holding Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    CorMedix Inc. Clarifies That No New Shares Are Being Issued In Connection With Its Recently Filed Form S-3 Registration Statement

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / October 18, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today clarified that contrary to certain erroneous news reports it is not issuing any new shares in connection with the S-3 filing filed on October 15, 2018. On October 15, 2018, the Company filed a Form S-3 registration statement to register an aggregate of 15,081,634 shares of its common stock issuable upon the exercise of Series B warrants with an exercise price of $1.05 and associated Underwriter warrants with an exercise price of $0.9375, both expiring on August 10, 2022, which were issued in connection with the Company's May 2017 underwritten public offering.

  • Simply Wall St.2 months ago

    What Kind Of Shareholders Own CorMedix Inc (NYSEMKT:CRMD)?

    The big shareholder groups in CorMedix Inc (NYSEMKT:CRMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable Read More...

  • ACCESSWIRE3 months ago

    CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 31, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the Exchange's continued listing standards set forth in Sections 1003(a)(i-iii) of the NYSE American Company Guide. CorMedix submitted its plan on July 16, 2018, and has been granted a plan period through December 16, 2019. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2018, CorMedix was notified on June 14, 2018, by the Exchange that the Company was not in compliance with Section 1003(a)(i)-(iii) related to insufficient stockholders' equity.

  • ACCESSWIRE3 months ago

    CorMedix Inc. to Present at The 20th Annual Rodman & Renshaw Global Investment Conference

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 30, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Khoso Baluch, President and Chief Executive Officer, accompanied by Paul Chew, M.D., Chief Medical Officer, will present a corporate overview with a focus on the Company's Neutrolin Phase 3 development program at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018 at the St. Regis New York Hotel in New York City.

  • Associated Press4 months ago

    CorMedix: 2Q Earnings Snapshot

    On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 10 cents. The pharmaceutical and medical device company posted revenue of $7,600 in the period. Its adjusted revenue ...

  • ACCESSWIRE4 months ago

    CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update

    - LOCK-IT-100 trial results positive; trial halted for efficacy - Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD), ...

  • ACCESSWIRE4 months ago

    CorMedix Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...

  • ACCESSWIRE4 months ago

    CorMedix Inc. to Report Second Quarter 2018 Financial Results on Tuesday, August 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 2, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE5 months ago

    Today's Research Reports on Stocks to Watch: USANA Health Sciences and CorMedix

    NEW YORK, NY / ACCESSWIRE / July 26, 2018 / It was a day of gains for both USANA Health Sciences Inc. and CorMedix. USANA reported record results for the second quarter while CorMedix announced the Data Safety Monitoring Board's positive review of the interim analysis of data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin. The company can now submit results to the Food & Drug Administration for review.

  • ACCESSWIRE5 months ago

    Cormedix Inc. Announces Positive Results Of Its Neutrolin(R) Phase 3 Lock-It-100 Study Based On Recommendation By Independent Data Safety Monitoring Board

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / July 25, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the interim analysis of the data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin®. Because the pre-specified level of statistical significance was reached and efficacy had been demonstrated, the DSMB recommended the study be terminated early.

  • ACCESSWIRE5 months ago

    Free Research Reports on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Lined up for scanning this morning are the following equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), CorMedix Inc. (NYSE AMER: CRMD), CRISPR Therapeutics AG (NASDAQ: CRSP), and Endocyte Inc. (NASDAQ: ECYT).

  • ACCESSWIRE6 months ago

    Today's Free Research Reports Coverage on CorMedix and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. This Monday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), Corcept Therapeutics Inc. (NASDAQ: CORT), CorMedix Inc. (NYSE AMER: CRMD), and CRISPR Therapeutics AG (NASDAQ: CRSP).

  • ACCESSWIRE6 months ago

    Cormedix Inc. Completes Review and Source Verification of Phase 3 Lock-It 100 Data For Neutrolin(R)

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 20, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its review and source-verification of the data required for the interim analysis of the Phase 3 LOCK-IT 100 study for Neutrolin®. The Company anticipates the database will be locked shortly and transferred to the independent biostatistician for unblinding and analysis. The independent biostatistician will then provide the results to the Data Safety Monitoring Board (DSMB) for its review, which is expected to occur in July 2018.

  • ACCESSWIRE6 months ago

    Cormedix Inc. Receives a Continued Listing Standard Notice from the NYSE American

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / June 19, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that on June 14, 2018, it received a notice from the NYSE American that, based on its Form 10-Q for the quarter ended March 31, 2018, filed on May 15, 2018, Cormedix does not meet a continued listing standard of the NYSE American as set forth in Part 10 of the NYSE American Company Guide.